Skip to main content

Alzheimer Disease News

News
12/17/2025
Lisa Kuhns, PhD, MD
Neuropsychiatric symptoms in Alzheimer disease are now widely viewed as core, treatable features of dementia rather than side effects, and experts say the field is shifting toward earlier recognition and more person-centered care, according...
Neuropsychiatric symptoms in Alzheimer disease are now widely viewed as core, treatable features of dementia rather than side effects, and experts say the field is shifting toward earlier recognition and more person-centered care, according...
Neuropsychiatric symptoms in...
12/17/2025
Annals of Long-Term Care
News
12/16/2025
Grace Taylor, MS, MA
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA...
12/16/2025
Annals of Long-Term Care
News
12/11/2025
Juliet Gallagher
A recent study highlights the expanding role of passive sensing technologies to assess subjective experiences—including agitation, sadness, and anhedonia—in persons living with Alzheimer disease and related dementias (AD/ADRD). As traditional...
A recent study highlights the expanding role of passive sensing technologies to assess subjective experiences—including agitation, sadness, and anhedonia—in persons living with Alzheimer disease and related dementias (AD/ADRD). As traditional...
A recent study highlights the...
12/11/2025
Annals of Long-Term Care
News
11/26/2025
Grace Taylor, MS, MA
A randomized trial shows that treating restless legs syndrome with gabapentin enacarbil can significantly reduce nighttime agitation and improve sleep in older adults with Alzheimer disease–related dementia.
A randomized trial shows that treating restless legs syndrome with gabapentin enacarbil can significantly reduce nighttime agitation and improve sleep in older adults with Alzheimer disease–related dementia.
A randomized trial shows that...
11/26/2025
Annals of Long-Term Care
News
11/20/2025
Grace Taylor, MS, MA
A national survey reveals that widespread misunderstanding of agitation in Alzheimer dementia is leaving millions of US caregivers emotionally drained, isolated, and struggling without adequate clinical support.
A national survey reveals that widespread misunderstanding of agitation in Alzheimer dementia is leaving millions of US caregivers emotionally drained, isolated, and struggling without adequate clinical support.
A national survey reveals that...
11/20/2025
Annals of Long-Term Care
News
11/10/2025
Juliet Gallagher
A 2024–2025 review of U.S. state medical cannabis programs found that Alzheimer disease (AD) and agitation associated with dementia remain qualifying conditions in 19 of 38 states. Despite this widespread policy inclusion, AD-related...
A 2024–2025 review of U.S. state medical cannabis programs found that Alzheimer disease (AD) and agitation associated with dementia remain qualifying conditions in 19 of 38 states. Despite this widespread policy inclusion, AD-related...
A 2024–2025 review of U.S. state...
11/10/2025
Annals of Long-Term Care
News
11/07/2025
Hannah Musick
A US caregiver survey found that nearly all individuals with Alzheimer disease exhibit agitated behaviors, which are strongly linked to increased caregiver burden, anxiety, depression, and reduced work productivity.
A US caregiver survey found that nearly all individuals with Alzheimer disease exhibit agitated behaviors, which are strongly linked to increased caregiver burden, anxiety, depression, and reduced work productivity.
A US caregiver survey found that...
11/07/2025
Annals of Long-Term Care
News
10/30/2025
Grace Taylor, MS, MA
A pooled analysis finds that 2 or 3 mg/day of brexpiprazole consistently reduces agitation symptoms across nearly all subgroups of patients with Alzheimer dementia.
A pooled analysis finds that 2 or 3 mg/day of brexpiprazole consistently reduces agitation symptoms across nearly all subgroups of patients with Alzheimer dementia.
A pooled analysis finds that 2...
10/30/2025
Annals of Long-Term Care
News
10/23/2025
Grace Taylor, MS, MA
Results from the phase 3 ACCORD-2 trial show that AXS-05 significantly delayed and prevented relapse of agitation in Alzheimer disease while maintaining a favorable safety profile.
Results from the phase 3 ACCORD-2 trial show that AXS-05 significantly delayed and prevented relapse of agitation in Alzheimer disease while maintaining a favorable safety profile.
Results from the phase 3...
10/23/2025
Annals of Long-Term Care
News
10/20/2025
Juliet Gallagher
Agitation is one of the most distressing and disruptive behavioral symptoms of Alzheimer dementia, affecting approximately one-half of all patients and placing a significant burden on caregivers and health care systems. In response to new...
Agitation is one of the most distressing and disruptive behavioral symptoms of Alzheimer dementia, affecting approximately one-half of all patients and placing a significant burden on caregivers and health care systems. In response to new...
Agitation is one of the most...
10/20/2025
Annals of Long-Term Care